PubMed Health⌕ Search

Biomedical subjects

J San Miguel

Publications and source records attributed to J San Miguel.

5 recordsLinked to original sources
PubMed1992

Developmental changes in rat liver mitochondrial populations analyzed by flow cytometry.

Isolated rat liver mitochondria were split into three density fractions when applied to a Percoll gradient. This phenomenon is observable in the fetus, in the early newborn (1 h), in the suckling newborn (7 days), and in the adult, suggesting that the three density fractions coexist regardless of the state of development. The medium-density fraction sharply decreased immediately after delivery, being replaced by the high-density fraction. Flow cytometry analysis of mitochondrial density fractions stained with rhodamine 123 showed the occurrence in each density fraction and in all developmental states studied of two distinct mitochondrial populations with different fluorescence intensities. Our results suggest that the high-fluorescence population might be an immature form of mitochondria that decreases with the progression of development, coinciding with the postnatal enhancement of mitochondrial respiratory efficiency.

Aging↗
PubMed1992

Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).

A total of 65 patients (35 male/30 female) with multiple myeloma primarily (33) or secondarily (32) resistant to melphalan and prednisone were treated with vincristine, carmustine (BCNU), doxorubicin, and high-dose dexamethasone (VBAD) at 4-week intervals. Among 60 evaluable patients the overall response was 36.6% (21.6% objective response plus 15% improvements). The response rate was significantly higher in primarily resistant patients than in those becoming resistant after a prior response (48.4 vs. 24.1%, P < 0.05). The median duration of response was 17.5 months. When survival of responders and non-responders were compared by the conventional method, a highly significant difference was observed (P < 0.001). However, using the Mantel and Byar procedure and the landmark method, only a trend for longer survival in the responders was registered. These results indicate that although VBAD is effective in at least one third of patients with advanced multiple myeloma resistant to melphalan, its impact on survival is limited.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1991

alpha Interferon in the management of essential thrombocythaemia.

Thirteen patients (mean age 60.7 years; female:male ratio 10:3) with essential thrombocythaemia were treated with 3 million units (MU)/day interferon alfa-2b subcutaneously (s.c.) for 12 weeks, with all patients requiring a dose reduction after 4 weeks. The mean pretreatment platelet count was 1,400 x 10(9)/L and megakaryocytes were increased in all cases. Splenomegaly was present in six patients and haemorrhagic phenomena were observed in two. Nine patients (69.2%) had objective responses, including two (15.4%) complete responses (platelets less than 450 x 10(9)/L) which were then maintained with 5 MU interferon twice a week. Acute toxicity consisted of flu-like symptoms in 12 patients. Chronic toxicity (mainly leucopenia) was observed in nine patients. In conclusion, initial therapy and then requiring maintenance therapy at a reduced dose. However, the frequent side effects observed make it advisable to use a low dose of interferon alfa-2b, and to treat only those patients with significant symptoms and signs of thrombocytosis.

Adult↗